



02-17-04

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/627,358
	Filing Date	July 25, 2003
	First Named Inventor	Peter Migaly
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	290194-00001

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Return Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Debra Z. Anderson
Signature	<i>Debra Z. Anderson</i>
Date	February 13, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Betsy A. Schreck
Signature	<i>Betsy A. Schreck</i>
Date	Feb. 13, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: : COMBINATION THERAPY FOR
: DEPRESSION, PREVENTION OF
PETER MIGALY : SUICIDE, AND VARIOUS MEDICAL
: AND PSYCHIATRIC CONDITIONS
Filed: July 25, 2003 :
: Serial No. 10/627,358
Attorney Docket No.: 290194-00001 :

INFORMATION DISCLOSURE STATEMENT

February 13, 2004


Mail Stop PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313


Sir:

Pursuant to the provisions of 37 CFR Sections 1.56, 1.97 and 1.98, Applicant submits herewith copies of the foreign patent document references and non-patent literature document references cited on the attached Forms PTO/SB/08A and PTO/SB/08B for consideration during prosecution of this application. These reference copies were submitted previously under documentation mailed February 11, 2004, to the United States Patent and Trademark Office in which the U.S. Patent Serial Number 10/627,358 was omitted.

This Statement is filed solely for the purpose of complying with the pertinent rules of the Office and is not intended to be a substitute for an independent evaluation by the Examiner of the art cited or an independent search by the Examiner, and no representation of any nature is made or intended by the filing of this Statement.

Respectfully submitted,


Debra Z. Anderson
Registration Number 44,506
Eckert Seamans Cherin & Mellott, LLC
600 Grant Street, 44th Floor
Pittsburgh, Pennsylvania 15219
Telephone: 412-566-1910
Attorney for Applicant



Please type plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet <u>3</u> of <u>3</u>				Complete if Known	
				Application Number	10/627,358
				Filing Date	July 25, 2003
				First Named Inventor	Peter Migaly
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	290194-00001

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AC	MICHAEL E. THASE, M.D.; "What Role Do Atypical Antipsychotic Drugs Have in Treatment-Resistant Depression?"; The Journal of Clinical Psychiatry; February, 2002; Pages 95-103; 63:2; Physicians Postgraduate Press, Inc., Memphis, Tennessee	
	AD	JAMBUR ANANTH; "Treatment-Resistant Depression"; Psychother Psychosom; 1998; Pages 61-70; 67; S. Karger AG, Basel, Switzerland	
	AE	D. SOUERY ET AL.; "Treatment resistant depression: methodological overview and operational criteria"; European Neuropsychopharmacology; 1999; Pages 83-91; 9; Elsevier Science B.V./ECNP; Amsterdam, The Netherlands	
	AF	MARK W. VINER, M.D. ET AL.; "Low-dose Risperidone Augmentation of Antidepressants in Nonpsychotic Depressive Disorders with Suicidal Ideation"; Journal of Clinical Psychopharmacology; February, 2003; Pages 104-106; Vol. 23, No. 1; Lippincott Williams & Wilkins; Philadelphia, Pennsylvania	
	AG	DE ADSON, M.D. ET AL.; "An Open Trial of Quetiapine for Anxiety in Patients Receiving an SSRI"; Society of Biological Psychiatry Annual Meeting; May 16-18, 2002; Philadelphia, Pennsylvania	
	AH	SHIGEHIO HIROSE, M.D. and CHARLES R. ASHBY, JR., PH.D.; "An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepressant Therapy"; Journal of Clinical Psychiatry; August, 2002; Pages 733-736; 63:8; Physicians Postgraduate Press, Inc., Memphis, TN	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.